CN111867628B - 抗cd73抗体及其用途 - Google Patents

抗cd73抗体及其用途 Download PDF

Info

Publication number
CN111867628B
CN111867628B CN201980018305.6A CN201980018305A CN111867628B CN 111867628 B CN111867628 B CN 111867628B CN 201980018305 A CN201980018305 A CN 201980018305A CN 111867628 B CN111867628 B CN 111867628B
Authority
CN
China
Prior art keywords
seq
ser
chain variable
variable region
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980018305.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN111867628A (zh
Inventor
王明晗
邹晖
裴芬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Van Enshi Pharmaceutical Beijing Co ltd
Original Assignee
Dongguan Fanshi Biomedical Co ltd
Van Enshi Pharmaceutical Beijing Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dongguan Fanshi Biomedical Co ltd, Van Enshi Pharmaceutical Beijing Co ltd filed Critical Dongguan Fanshi Biomedical Co ltd
Priority to CN202411072731.7A priority Critical patent/CN118955714A/zh
Publication of CN111867628A publication Critical patent/CN111867628A/zh
Application granted granted Critical
Publication of CN111867628B publication Critical patent/CN111867628B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Fats And Perfumes (AREA)
CN201980018305.6A 2018-03-09 2019-03-05 抗cd73抗体及其用途 Active CN111867628B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411072731.7A CN118955714A (zh) 2018-03-09 2019-03-05 抗cd73抗体及其用途

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862640955P 2018-03-09 2018-03-09
US62/640,955 2018-03-09
US201862721044P 2018-08-22 2018-08-22
US62/721,044 2018-08-22
US201862786598P 2018-12-31 2018-12-31
US62/786,598 2018-12-31
PCT/US2019/020688 WO2019173291A1 (en) 2018-03-09 2019-03-05 Anti-cd73 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411072731.7A Division CN118955714A (zh) 2018-03-09 2019-03-05 抗cd73抗体及其用途

Publications (2)

Publication Number Publication Date
CN111867628A CN111867628A (zh) 2020-10-30
CN111867628B true CN111867628B (zh) 2024-08-23

Family

ID=67846304

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980018305.6A Active CN111867628B (zh) 2018-03-09 2019-03-05 抗cd73抗体及其用途
CN202411072731.7A Pending CN118955714A (zh) 2018-03-09 2019-03-05 抗cd73抗体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411072731.7A Pending CN118955714A (zh) 2018-03-09 2019-03-05 抗cd73抗体及其用途

Country Status (13)

Country Link
US (1) US11299550B2 (https=)
EP (1) EP3762030A4 (https=)
JP (2) JP7334177B2 (https=)
KR (2) KR102804816B1 (https=)
CN (2) CN111867628B (https=)
AU (1) AU2019231172B2 (https=)
BR (1) BR112020016049A2 (https=)
CA (1) CA3090008A1 (https=)
IL (1) IL276950B2 (https=)
MX (1) MX2020009366A (https=)
SG (1) SG11202007199XA (https=)
WO (1) WO2019173291A1 (https=)
ZA (1) ZA202004827B (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019067425A1 (en) 2017-09-26 2019-04-04 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR TREATING CARDIAC DISEASE BY REDIRECTED T-CELL IMMUNOTHERAPIES
TWI877770B (zh) 2018-02-27 2025-03-21 美商英塞特公司 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
WO2020010197A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
EP3861018A4 (en) 2018-10-05 2022-10-26 Seattle Children's Hospital d/b/a Seattle Children's Research Institute NEWBORN SCREENING FOR PRIMARY IMMUNODEFICIENCY CYSTINosis AND WILSON'S DISEASE
CN111434688A (zh) * 2019-01-11 2020-07-21 上海开拓者生物医药有限公司 Cd73抗体及其制备方法和应用
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US12116418B2 (en) 2019-09-23 2024-10-15 The Trustees Of The University Of Pennsylvania Disrupting tumor tissues by targeting fibroblast activation protein (FAP)
MX2022003465A (es) 2019-09-23 2022-06-16 Univ Pennsylvania Anticuerpo monoclonal contra proteína de activación de fibroblasto canino de reacción cruzada con proteína de activación de fibroblasto (fap) de ratón y humana.
CA3161717A1 (en) * 2019-11-15 2021-05-20 Dana LORD Biparatopic cd73 antibodies
EP4061420A1 (en) * 2019-11-20 2022-09-28 Abvision, Inc. Monoclonal antibodies that target human cd47 protein
CA3160436A1 (en) * 2019-12-17 2021-06-24 Jack Chongyang LI Bispecific antibodies with alternatively matched interchain cysteines and uses thereof
TW202135823A (zh) 2020-01-03 2021-10-01 美商英塞特公司 Ｃｄ７３抑制劑及ａ２ａ／ａ２ｂ腺苷受體抑制劑組合療法
PE20221409A1 (es) * 2020-01-03 2022-09-20 Incyte Corp Anticuerpos anti-cd73 y usos de estos
JP2023519969A (ja) 2020-03-31 2023-05-15 シアトル・チルドレンズ・ホスピタル・ドゥーイング／ビジネス／アズ・シアトル・チルドレンズ・リサーチ・インスティテュート リソソーム蓄積症に関するプロテオミクススクリーニング
US12523662B2 (en) 2020-04-02 2026-01-13 Seattle Children's Hospital Antibodies that specifically bind peptides associated with the primary immunodeficiencies: Wiskott-Aldrich syndrome and x-linked agammaglobulinemia
CA3176321A1 (en) * 2020-04-22 2021-10-28 Peng Zhang Anti-cd73-anti-pd-1 bispecific antibody and use thereof
US20230159655A1 (en) * 2020-04-22 2023-05-25 Akeso Biopharma, Inc Anti-cd73 antibody and use thereof
BR112022021992A2 (pt) * 2020-04-30 2023-01-03 Arch Oncology Inc Método de tratamento de câncer em um sujeito em necessidade do mesmo
US20240218074A1 (en) * 2020-08-17 2024-07-04 Akeso Biopharma, Inc. Anti-cd73 antibody and use thereof
CN120590533A (zh) * 2020-10-23 2025-09-05 中山康方生物医药有限公司 抗cd73的抗体及其用途
CN114456268B (zh) * 2020-11-09 2023-08-18 江苏中新医药有限公司 抗胞外-5’-核苷酸酶的抗体序列
TWI900705B (zh) * 2020-12-11 2025-10-11 大陸商上海華奧泰生物藥業股份有限公司 Ｃｄ７３的抗原結合蛋白及其應用
TW202241441A (zh) 2020-12-29 2022-11-01 美商英塞特公司 包含ａ２ａ／ａ２ｂ抑制劑、ｐｄ－１／ｐｄ－ｌ１抑制劑及抗ｃｄ７３抗體之組合療法
CN113061177B (zh) * 2020-12-31 2022-07-01 浙江大学 一种cd73酶活性相关的抗原表位及针对该表位的特异性抗体的制备方法
US20240174763A1 (en) * 2021-02-24 2024-05-30 Novoprotein Scientific Inc. Anti-human cd73 antibody and use thereof
GB202105110D0 (en) * 2021-04-09 2021-05-26 Cancer Research Tech Ltd Anti-CD73 antibodies
WO2023023354A2 (en) * 2021-08-19 2023-02-23 Adicet Therapeutics, Inc. Methods for detection of membrane bound glypican-3
CN116265486A (zh) * 2021-12-17 2023-06-20 三生国健药业（上海）股份有限公司 结合人cd73的抗体、其制备方法和用途
US12187806B2 (en) * 2022-03-04 2025-01-07 Development Center For Biotechnology Anti-CD73 antibodies and use thereof
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN116063467B (zh) * 2022-08-24 2025-10-14 浙江大学医学院附属第一医院 抗h10亚型禽流感病毒血凝素蛋白单克隆抗体1f3及其在检测中的应用
WO2024243189A2 (en) * 2023-05-22 2024-11-28 Board Of Regents, The University Of Texas System Antigen binding proteins targeting pd-1
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
CN117567632B (zh) * 2023-11-27 2025-10-24 福州迈新生物技术开发有限公司 抗cd73蛋白单克隆抗体及其制备方法和应用
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025233264A1 (en) 2024-05-07 2025-11-13 Innate Pharma Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001472A (zh) * 2014-11-10 2017-08-01 免疫医疗有限公司 对cd73具有特异性的结合分子及其用途
EP3221363A2 (en) * 2014-11-21 2017-09-27 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5382692B2 (ja) 2006-07-10 2014-01-08 学校法人藤田学園 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途
FR3011240A1 (fr) 2013-10-01 2015-04-03 Centre Nat Rech Scient Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques
MA39986A (fr) 2014-04-25 2017-03-01 Vitae Pharmaceuticals Inc Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
WO2016131950A1 (en) * 2015-02-20 2016-08-25 Innate Pharma Cd73 blockade
EP3204417B1 (en) 2014-10-10 2020-07-22 Innate Pharma Cd73 blockade
GB2538120A (en) 2014-11-11 2016-11-09 Medimmune Ltd Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
JP6668345B2 (ja) 2014-11-21 2020-03-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 修飾された重鎖定常領域を含む抗体
US11130817B2 (en) 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
CN114805575B (zh) * 2015-12-09 2024-07-23 科尔沃斯制药股份有限公司 人源化抗cd73抗体
WO2017118613A1 (en) 2016-01-08 2017-07-13 Syddansk Universitet Bispecific antibodies targeting human cd73
EP3423494A1 (en) * 2016-03-04 2019-01-09 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
WO2018013611A1 (en) 2016-07-11 2018-01-18 Corvus Pharmaceuticals, Inc. Anti-cd73 antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001472A (zh) * 2014-11-10 2017-08-01 免疫医疗有限公司 对cd73具有特异性的结合分子及其用途
EP3221363A2 (en) * 2014-11-21 2017-09-27 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof

Also Published As

Publication number Publication date
US11299550B2 (en) 2022-04-12
EP3762030A1 (en) 2021-01-13
IL276950A (en) 2020-10-29
SG11202007199XA (en) 2020-09-29
CN118955714A (zh) 2024-11-15
ZA202004827B (en) 2023-06-28
IL276950B2 (en) 2026-04-01
EP3762030A4 (en) 2022-01-05
US20200399389A1 (en) 2020-12-24
KR20200128542A (ko) 2020-11-13
AU2019231172A1 (en) 2020-09-03
MX2020009366A (es) 2020-10-14
JP7334177B2 (ja) 2023-08-28
JP2021516057A (ja) 2021-07-01
BR112020016049A2 (pt) 2020-12-08
IL276950B1 (en) 2025-12-01
JP7636483B2 (ja) 2025-02-26
JP2023162257A (ja) 2023-11-08
CA3090008A1 (en) 2019-09-12
WO2019173291A1 (en) 2019-09-12
KR102804816B1 (ko) 2025-05-09
NZ766968A (en) 2024-12-20
AU2019231172B2 (en) 2023-08-24
CN111867628A (zh) 2020-10-30
KR20250065424A (ko) 2025-05-12

Similar Documents

Publication Publication Date Title
CN111867628B (zh) 抗cd73抗体及其用途
CN111183155B (zh) 抗cd47抗体及其用途
US11214615B2 (en) Anti-TIM-3 antibodies and uses thereof
CN112584860B (zh) 抗dll3抗体及其用途
CN111050792B (zh) 抗lag-3抗体及其用途
BR112020016469A2 (pt) Anticorpos do receptor anti-folato 1 e seus usos
HK40031477A (en) Anti-cd73 antibodies and uses thereof
HK40119299A (zh) 抗cd73抗体及其用途
HK40031477B (zh) 抗cd73抗体及其用途
EA043284B1 (ru) Антитела против cd73 и их применения
HK40033064A (en) Anti-folate receptor 1 antibodies and uses thereof
HK40033064B (en) Anti-folate receptor 1 antibodies and uses thereof
HK40039992A (en) Anti-dll3 antibodies and uses thereof
HK40017927A (en) Anti-tim-3 antibodies and uses thereof
HK40019844A (en) Anti-lag-3 antibodies and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40031477

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240516

Address after: Room 2218, 2nd Floor, Building 2, No. 88 Kechuang 6th Street, Beijing Economic and Technological Development Zone, Tongzhou District, Beijing, 101111

Applicant after: Van Enshi Pharmaceutical (Beijing) Co.,Ltd.

Country or region after: China

Address before: 523808 Floor 3 and 4, Office Building 3, Zone A, Zhongda Marine Biotechnology R&D Base, No. 9, Xincheng Avenue, Dongguan Songshan Lake Hi tech Industrial Development Zone, Dongguan, Guangdong

Applicant before: Dongguan Fanshi biomedical Co.,Ltd.

Country or region before: China

GR01 Patent grant
GR01 Patent grant